To support or not to support – supplements in dogs with advanced heart failure
Magdalena Garncarz, DVM PhD, Marta Parzeniecka-Jaworska DVM PhD
Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine,
Warsaw University of Life Sciences – SGGW, Poland
Supplementary therapy for patients with heart diseases has been in use for a long time in diﬀerent forms. Some of the products available commercially include L-carnitine, a substance necessary for correct metabolism of fatty acids and energy production; taurine that plays a crucial role in normal function of the heart; Q10 coenzyme (ubiquinone), important in energy metabolism of the heart; and vitamin E that – just like Q 10 coenzyme or taurine – has got a strong antioxidative properties. In dogs with different stages of heart insufciency it is difcult to compare the eﬀect of action of these substances themselves without resorting to standard therapy, that is diuretics, inodilators, inhibitors of angiotensin converting enzymes, and antiarrhythmic drugs. Therefore the authors attempted at evaluating how dogs with heart diseases of diﬀerent stages feel.
MATERIALS AND METHODS
The study was performed on 36 dogs of diﬀerent breeds, aged from 36 to 222 months, 10 females, 26 males. Majority of dogs were diagnosed with chronic mitral valve disease (CMVD, 25 dogs), while others with dilated cardiomyopathy (DCM, 11 dogs). All dogs had transthoracic echocardiographic test performed. Moreover, x-ray was performed to evaluate the presence of left sided congestive heart failure. The stage of heart insufciency was determined based on accepted standards, following classifcation of International Small Animal Cardiac Health Council (ISACHC). According to this classifcation, dogs with CMVD or DCM were qualifed as class 1 (asymptomatic, n = 9), class 2 (mild to moderate heart failure, n = 16) or class 3 (advanced heart failure, n = 11). On the day of the visit, dogs classifed as ISACHC 2 and 3 received a supplement for dogs with heart failure to complement standard therapy. The composition of the supplement includes: L-Carnitine tartrate 500 mg, taurine 200 mg, Q10 coenzyme 10 mg and vitamin E 60 IU/pill (CardioVet, VetExpert). The product was administered according to producer’s recommendations. After a month, during the follow-up visit, the owners were asked to describe their observations about how the dogs felt, focusing on their eﬀort tolerance during walks, respiratory symptoms (tachypnoea) and coughing.
Out of nine dogs classifed as ISACHC 1, owners of three patients observed improved ftness, describing their dogs as being more lively after administration of the supplement, as compared to the period prior to administration (33.3% of ISACHC 1 dogs, 8.3% of all studied dogs). According to the owners, in 12 out of 16 ISACHC 2 dogs eﬀort tolerance improved – the owners described their dogs as more lively (75% of ISACHC 2 dogs, 33.3% of all studied dogs). This group included eight dogs with CMVD and four dogs with DCM. As regards 11 dogs with the advanced heart failure, namely ISACHC class 3, in nine patients eﬀort tolerance improved (81.8% of ISACHC 3
dogs, 25% of all studied dogs). This group included two out of three dogs with DCM and 7 out of 8 dogs with CMVD. In two dogs (one with CMVD, one with DCM) cough frequency decreased (18.2% of ISACHC 3 dogs, 5.6% of all studied dogs).
The study showed favorable eﬀect of the analysed product on sick animals with advanced heart failure. The studied product led to improved eﬀort tolerance in majority of dogs, although the evaluation of the eﬀort tolerance was based on subjective impressions of the owners. The owners did not observe adverse eﬀects of the product. The pills were well tolerated, with no adverse eﬀects. Only rarely the problem was the size of the pill. In small breeds it is necessary to crash the pill and administer it mixed with food or water. This study shows good tolerance and eﬀects of the complex product – CardioVet, particularly in dogs with advanced heart failure.